Using data and AI to predict risk of sleep apnea: Quick Note

Research evidence excerpt

Using data and AI to predict risk of sleep apnea: Quick Note

Global Markets Research

24 June 2026JMDC

4483.T 4483 JP / EQUITY: JAPAN PHARMACEUTICALS

RatingUsing data and AI to predict risk of sleep apnea Buy

Target price JPY 5,380Quick Note

Closing price

24 June 2026 JPY 2,695JMDC, Omron, and University of Tsukuba develop model for predicting risk of sleep

apnea syndrome (Note: Quick Note reports are not a

On 24 June JMDC announced that it had developed an AI model together with Omron vehicle for changes to ratings, target

[6645] (Neutral) and the University of Tsukuba to predict the risk of sleep apnea syndrome prices, or earnings forecasts)

with a high degree of precision using health insurance claims, health check-ups, and life

log data, and that this had been detailed in a paper in the journal SleepandBreathing.

There are roughly 9.4mn potential sleep apnea sufferers in Japan, of which only around

640,000 are being treated with continuous positive airway pressure (CPAP). Gauging the

Research Analystsrisk of sleep apnea at present requires substantial effort and costs in the form of detailed

tests or investigations using wearable devices based on people's subjective symptoms. Japan pharmaceuticals &

healthcare

Good example of using AI to make full use of vast amounts of high-quality data Kyoichiro Shigemura - NSC

This research project applied machine learning to JMDC's insurance claims data, check- kyoichiro.shigemura@nomura.com

up data, and life log data from around 1.86mn people registered with Pep Up, and applied +81 3 6703 1118

machine learning to predict sleep apnea symptoms that would require treatment. Indeed,

28% of the people in the top 1% in terms of forecast score were actually receiving CPAP

treatment for sleep apnea.